Edition:
United Kingdom

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

17.94USD
11 Dec 2018
Change (% chg)

-- (--)
Prev Close
$17.94
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
102,222
52-wk High
$31.69
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Apellis Pharmaceuticals Reports Q2 Loss Per Share Of $0.61
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS SECOND QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.61.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM CONSISTING OF 2 TRIALS OF APL-2 IN GEOGRAPHIC ATROPHY REMAINS ON TRACK TO BEGIN IN H2 2018.APELLIS PHARMACEUTICALS INC - AS OF JUNE 30, 2018, APELLIS HAD $253.8 MILLION IN CASH & CASH EQUIVALENTS VERSUS $152.9 MILLION AS OF MARCH 31, 2018.  Full Article

Apellis Pharma's APL-2 Receives Fast Track Designation From FDA
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS’ APL-2 RECEIVES FAST TRACK DESIGNATION FROM FDA FOR THE TREATMENT OF PATIENTS WITH GEOGRAPHIC ATROPHY.APELLIS PHARMACEUTICALS - APELLIS PLANS TO INITIATE A PHASE 3 TRIAL FOR PATIENTS WITH GA LATER IN 2018.  Full Article

Apellis Pharma Provides Update On Two Phase Ib Trials For Patients With PNH
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON TWO PHASE IB TRIALS FOR PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH).APELLIS - SEVERELY ANEMIC PATIENTS WITH PNH ON TREATMENT WITH SOLIRIS CAN BECOME TRANSFUSION-FREE WHEN SWITCHED TO APL-2 MONOTHERAPY.APELLIS - TREATMENT-NAÏVE PATIENTS WITH PNH SHOW CLINICALLY MEANINGFUL IMPROVEMENTS FOR ALL HEMATOLOGICAL PARAMETERS WHEN TREATED WITH APL-2.APELLIS - SUBCUTANEOUS APL-2 HAS GENERALLY BEEN WELL-TOLERATED WITH CUMULATIVE SYSTEMIC EXPOSURE OF OVER 12 PATIENT YEARS OF TREATMENT ON APL-2.  Full Article

Apellis Pharmaceuticals Announces Pricing Of Offering Of Common Stock
Thursday, 19 Apr 2018 

April 18 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF OFFERING OF COMMON STOCK.APELLIS PHARMACEUTICALS- PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 5.5 MILLION SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $25.50 PER SHARE.  Full Article

Apellis Pharmaceuticals Provides Update On Phase 1B Open Label Study Of APL-2 In Pnh Patients Not Previously Treated With Eculizumab
Monday, 16 Apr 2018 

April 16 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB.APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS.APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE.APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB.  Full Article

Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM EVALUATING APL-2 PLANNED TO BEGIN IN SECOND HALF OF 2018.APELLIS PHARMACEUTICALS - PHASE 3 PROGRAM TO CONSIST OF TWO IDENTICAL 600-PATIENT STUDIES TO ASSESS EFFICACY,SAFETY.APELLIS PHARMACEUTICALS INC - PHASE 3 TRIALS EVALUATING APL-2 WILL BE SUBSTANTIALLY SIMILAR IN DESIGN TO APELLIS' ONGOING PHASE 2 FILLY TRIAL.  Full Article

Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Apellis Pharmaceuticals Inc :Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing.  Full Article

Apellis Pharmaceuticals announces closing of its IPO
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::Apellis pharmaceuticals announces closing of its initial public offering.  Full Article

Apellis Pharma shares debut about 3.6 pct above IPO price
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - :Apellis Pharmaceuticals Inc shares open at $14.50 in debut on the NASDAQ versus IPO price of $14 per share‍​.  Full Article

Apellis prices IPO of 10.7 mln common shares at $14/shr
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Apellis Pharmaceuticals Inc :Apellis Pharmaceuticals announces pricing of initial public offering.Says initial public offering of 10.7 million common shares priced at $14.00 per share.  Full Article